Marlies M. Kok

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Clemens von Birgelen, Marlies M. Kok, Liefke C. van der Heijden et al. · The Lancet · 2016 · 246 citations · Full text

Percutaneous Coronary Intervention, Cardiovascular Disease, Atherosclerosis +8

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

Clemens von Birgelen, Paolo Zocca, Rosaly A. Buiten et al. · The Lancet · 2018 · 145 citations · Full text

Percutaneous Coronary Intervention, Endovascular Technique, Cardiovascular Disease +7

Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study

Marlies M. Kok, Marieke G.M. Weernink, Clemens von Birgelen et al. · Catheterization and Cardiovascular Interventions · 2017 · 100 citations · Full text

Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial

Liefke C. van der Heijden, Marlies M. Kok, Peter W. Danse et al. · American Heart Journal · 2016 · 72 citations · Full text

Percutaneous Coronary Intervention, Thrombosis, Twente Ii +9

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels

Rosaly A. Buiten, Eline H. Ploumen, Paolo Zocca et al. · JAMA Cardiology · 2019 · 70 citations · Full text